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Abstract
This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer
patients in the UK. Recurrent cancers present some of the most challenging management issues in head and
neck surgical and oncological practice. This is rendered even more complex by the poor evidence base to
support management options, the substantial implications that treatments can have on the function and quality of
life, and the difficult decision-making considerations for supportive care alone. This paper provides consensus
recommendations on the management of recurrent head and neck cancer.
Recommendations
• Consider baseline and serial scanning with computed tomography and/or magnetic resonance (CT and/or MR)
to detect recurrence in high-risk patients. (R)
• Patients with head and neck cancer recurrence being considered for active curative treatment should undergo
assessment by positron emission tomography combined with computed tomography (PET–CT) scan. (R)
• Patients with recurrence should be assessed systematically by a team experienced in the range of management
options available for recurrence including surgical salvage, re-irradiation, chemotherapy and palliative care. (R)
• Management of patients with laryngeal recurrence should include input from surgeons with experience in
transoral surgery and partial laryngectomy for recurrence. (G)
• Expertise in transoral surgery and partial laryngectomy for recurrence should be concentrated to a few surgeons
within each multidisciplinary teams. (G)
• Transoral or open partial laryngectomy should be offered as definitive treatment modality for highly-selected
patients with recurrent laryngeal cancer. (R)
• Patients with OPC recurrence should have p16 human papilloma virus status assessed. (R)
• Patients with OPC recurrence should be considered for salvage surgical treatment by an experienced team, with
reconstructive expertise input. (G)
• Transoral surgery appears to be an effective alternative to open surgery for the management of OPC recurrence
in carefully selected patients. (R)
• Consider elective selective neck dissections in patients with recurrent primaries with N0 necks, especially in
advanced cases. (R)
• Selective neck dissection (with preservation of nodal levels, especially level V, that are not involved by disease)
in patients with nodal (N+) recurrence appears to be as effective as modified or radical neck dissections. (R)
• Use salivary bypass tubes following salvage laryngectomy. (R)
• Use interposition muscle-only pectoralis major or free flap for suture line reinforcement if performing primary
closure following salvage laryngectomy. (R)
• Use inlaid pedicled or free flap to close wound if there is tension at the anastomosis following laryngectomy. (R)
• Perform secondary puncture in post chemoradiotherapy laryngectomy patients. (R)
• Triple therapy with platinum, cetuximab and 5-fluorouracil (5-FU) appears to provide the best outcomes for the
management of patients with recurrence who have a good performance status and are fit to receive it. If not fit,
then combinations of platinum and cetuximab or platinum and 5-FU may be considered. (R)
• Patients with non-resectable recurrent disease should be offered the opportunity to participate in phases I–III
clinical trials of new therapeutic agents. (R)
• Chemo re-irradiation appears to improve locoregional control, and may have some benefit for overall survival,
at the risk of considerable acute and late toxicity. Benefit must be weighed carefully against risks, and patients
must be counselled appropriately. (R)
• Target volumes should be kept tight and elective nodal irradiation should be avoided. (R)
• Best supportive care should be offered routinely as part of the management package of all patients with
recurrent cancer even in the case of those who are being treated curatively. (R)
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Introduction
Traditionally patients with recurrence of head and neck
cancer (HNC) are considered to have poor prognosis.
As a result the majority of these patients are usually
treated with palliative intent or receive best supportive
care.
Recent systematic review of the literature would
suggest, however, that outcomes of the management
of recurrence are not as dire as is widely considered.
For example, the management of laryngeal recurrence
is reported to have good outcomes with rates of up to
71 per cent two-year overall survival.1 A recent meta-
analysis shows that the outcomes of management of
oropharyngeal cancer recurrence appear to have
improved significantly over the last two decades, reach-
ing five-year survival of 50 per cent in patients treated
surgically.2 The latter may be the result of a combin-
ation of better patient selection, improved surgical
care and the role of the human papilloma virus
(HPV) as an aetiological factor.
These improvements in outcomes suggest the need
for re-appraisal of the treatment paradigms of HNC
recurrence, and the development of specific expertise
in the management of recurrence including probably
the concentration of expertise in centralised regional
or super-regional services.
Evaluation of the patient with recurrence
Evaluation and careful selection of patients with recur-
rence is the crux of successful management.3 There are
several steps in the evaluation process of these patients.
History
It is important to elucidate the details of the previous
treatments that the patient has had, including the chron-
ology and duration since previous treatment. It is also
important to identify any toxicity that the patient has
experienced from previous treatments as this may
have a bearing on any new treatments being offered.
The patient’s past medical history, and current morbid-
ities and general health state are important, as these will
help determine whether the patient is fit enough to
receive further curative or palliative active treatments.
A smoking and alcohol intake history should be
taken. This should especially ascertain whether the
patient is currently still smoking or drinking heavily.
Finally, a social history of the patient’s activities of
daily living and their requirements in terms of speech
and mobility, as well as their social support structures
are important in determining their ability to cope with
the demanding treatments that may be required for
the management of the recurrence.
Assessment and staging
Clinical examination. Even under anaesthetic, examin-
ation can be deceiving if relied upon solely. One study
showed a false negative rate of 31 per cent for examin-
ation under anaesthetic (EUA) biopsies in 131 patients
who showed recurrence within six months of EUA.
However, following identification of potential recur-
rence by scanning, EUA can help provide more infor-
mation regarding the feasibility of surgical resection
and aid planning. Furthermore, a biopsy can be used
to assess HPV status, which recently has been found
to be of prognostic value in patients with recurrence.4
In the longer term, as personalised medicine develops,
molecular profiling of the recurrent tumour may
provide insights into themost appropriate systemic treat-
ments for that particular tumour.
Performance status and co-morbidities Assessment
of the patient’s overall fitness for anaesthetic and/or
systemic therapy is necessary, as that is likely to be
an important determinant of whether the patient is
able to receive additional treatment in both a curative
and a palliative setting.
Imaging Positron emission tomography combined
with computed tomography (PET–CT) scanning can
be extremely helpful in the assessment of recurrence
as it can identify the areas of local and nodal recur-
rence, and importantly distant metastasis. The negative
predictive value of PET–CT scan is especially high for
recurrence at both the primary site and the neck,
approaching values between 93 and 95 per cent and
94 and 100 per cent respectively.5 A meta-analysis
also showed high sensitivity and specificity for detec-
tion of distant metastasis in patients with recurrent
HNC (0.92 and 0.95 respectively),6 and PET–CT scan-
ning can change the management in 20 per cent of
patients with HNC recurrence. In one study, 24 of
123 patients were identified to have silent recurrence
or metastasis by PET–CT, of which 50 per cent had
thoracic metastasis and 32 per cent had distant metasta-
sis in other sites7.
A single CT scan or magnetic resonance imaging
(MRI) scan has low accuracy for differentiating
between cancer, oedema, and interstitial radiation
fibrosis and necrosis. Additional imaging such as an
MRI or contrast CT scanning may however be import-
ant for planning surgical procedures and outlining
radiotherapy (RT).
Recommendations
• Consider baseline and serial scanning with
CT or MRI to detect recurrence in high risk
patients (R)
• Patients with HNC recurrence being
considered for active curative treatment
should undergo assessment by PET CT scan
(R)
Decision making for treatment
By combining the findings of the patient assessment
process, the following factors need to be considered
to help select cases that are appropriate for curative
treatment.3
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• What was the previous disease and what were the
treatments given? A review of the extent and fea-
tures of the previous disease including any poor
prognostic features and involved margins is neces-
sary. Furthermore, it is important to elucidate the
details of the previous treatment including the
levels of neck dissection, the radiotherapy (RT)
fields and doses as well as ascertaining any geo-
graphic misses and the time since treatment.
• Is there any evidence of distant metastasis? This
severely limits the possibility of cure and therefore
affects the choice and aggressiveness of treatments
to be offered.
• Is it a recurrence at the primary site or a second
primary tumour? It is important to ascertain the
extent and the size of the recurrence of the
primary tumour. Recurrence of a previous
tumour has a poorer outcome than a second
primary. Furthermore, recurrences in the orophar-
ynx have significantly poorer outcomes than those
in the larynx.
• Is there recurrence in the neck?What are the extent
and the size of the neck recurrence and is there any
evidence of soft tissue extension or extracapsular
nodal extension by physical examination and on
imaging? The presence of extracapsular extension
without the ability to give additional adjuvant
treatment significantly reduces the chance of
cure and survival.8
• Is there evidence of involvement of the carotid
arteries, brachial plexus and prevertebral
muscles? Involvement of these makes surgical
resection unlikely and curative resection almost
impossible.
• Can the recurrence be excised surgically with no
gross tumour left behind?
• Are there complications and toxicity of previous
treatment evident, including osteoradionecrosis
or dysphagia? If there are, then the addition of
further treatment may result in considerable tox-
icity and quality of life detriment.
• Is it possible to give RT and/or chemotherapy,
taking into account previous treatment, resultant
toxicities and time of last treatment?
• What are the potential functional deficits of the
proposed treatment for the recurrence?
• What is the state of the patient’s reserve, psycho-
logical state, general health and family and
social support? These factors will be important
to consider if the patient is fit and able to
undergo further treatment.
Patient selection criteria
Studies on the outcomes and prognostic factors for the
treatment of head and neck recurrence are generally
retrospective and of poor quality. They have described,
however, several predictors of good outcomewhich can
be classified under three main themes: patient factors,
treatment factors and tumour factors.
Patient factors
The patient factor predictors of good outcome include
patients who are non-smokers or who have stopped
smoking, have good general heath (ECOG (Eastern
Cooperative Oncology Group) status 0–1) and
minimal comorbidities,9 a good psychological state,
good family support, those who are married, and
those who are religious or spiritual.
Tumour factors
Patients with laryngeal recurrence or second primary
tumours have better outcomes. Patients with small loca-
lised tumours (low T stage (rT1–T2) and a low overall
stage8 and those with no neck disease on recurrence
demonstrate better outcomes. Patients with no nodal
extracapsular spread also have better outcomes.
Patients who have a recurrence more than 12 months
after the end of their treatment appear to do better.
Those with recurrence less than six months from treat-
ment completion have persistent disease and a much
worse prognosis.8 Finally, patients who have HPV
positive recurrent disease have longer survival follow-
ing treatment for recurrence.4
Treatment factors
Patients having surgical resection,2,4 who have received
no previous RT or chemotherapy8,9 or have not experi-
enced severe ongoing toxicity from previous treatment
appear to have the best outcomes, especially if they
have HPV-positive disease.4 Patients with resectable
disease with no gross tumour remaining after resection
and no involved surgical margins8 also demonstrate
better outcomes, as do patients with no involved vital
structures.
Surgery
General principles
From the data available, surgery appears to be the
modality that is likely to result in the best chance of
cure,2 especially if there is the possibility of receiving
adjuvant treatment post-operatively,8 or if the patient
has HPV-positive disease.4 The aim of surgical treat-
ment is to remove the whole tumour with wide clear
margins, leaving no gross residual tumour behind.
However, this will usually result in large defects requir-
ing reconstruction. The resulting large functional defi-
cits have to be balanced against the benefit of longer
survival and/or or improved palliation.
Surgical salvage is associated with high complica-
tion rates and morbidities. The Radiation Therapy
Oncology Group (RTOG) 91–11 study reported an
overall complication rate of 59 per cent, of which 19
per cent were classified as major complications.1 A
fistula rate of 30 per cent was reported following
salvage laryngectomy after chemoradiotherapy, and
15 per cent if they had been treated with RT. The
MDAnderson series of oropharyngeal salvage reported
an overall complication rate of 48 per cent.8 As a result
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of that and slower wound healing, patients experience
long stays in hospital, which they need to be fore-
warned about. Such treatment also carries significant
costs, which need to be accounted for in reimburse-
ment. Specific interventions that have been shown to
reduce complication rates are discussed below.
Recommendation
• Patients with recurrence should be assessed
systematically by a team experienced in the
range of management options available for
recurrence including surgical salvage,
re-irradiation, chemotherapy and palliative
care (R)
It is important to note that patients should undergo
appropriate and extensive counselling regarding
expected survival and functional outcomes, including
the long post-operative hospital stays and high compli-
cation rates. Early involvement of palliative care physi-
cians in the counselling and treatment of patients, even
in situations where curative treatments are being
offered, is of benefit to control symptoms and
provide psychological support.
Site-specific factors
Larynx. Total laryngectomy is a highly feasible and
effective treatment for laryngeal recurrence. In the
RTOG 91–11 study, 122 patients recurred after RT or
chemoradiotherapy, all of whom had salvage total lar-
yngectomy. The study reported two-year locoregional
control rates of 74 per cent and two-year overall sur-
vival of 71 per cent.1 However, it should be noted
that there are several other feasible and highly effective
modalities for the treatment of laryngeal recurrence that
may also allow preservation of organ function.
Transoral laser surgery has been found to be very
effective in well-selected patients. In a study of 34
recurrent T1–T4 post-RT failures, 71 per cent were
reported to be cured with one or more transoral laser
procedure, 29 per cent of patients had tumours that
could not be controlled, of which 18 per cent required
total laryngectomy and 9 per cent required palliative
treatment.10 In another study of 53 T1–T4 tumours that
recurred after RT,11 42per centwere curedwith one trans-
oral procedure and 16 per cent required more than one
procedure, 26 per cent could not be controlled and
required total laryngectomy and 11 per cent could not
undergo total laryngectomy for recurrence and required
palliative treatment. Transoral surgery should however
be performed in selected cases by experienced surgeons,
as a meta-analysis of transoral laser surgery for radiore-
current cancers showed around 30 per cent inferior
local control comparedwith open partial laryngectomy.12
A systematic review and meta-analysis of 554
patients who underwent salvage open partial laryngect-
omy concluded that the pooled locoregional control
rate was 87.2 per cent (83.3–90 per cent). Pooled
overall survival was 83.5 per cent (79.4–87.3 per
cent), with a pooled disease-free survival of 91.4 per
cent (88.0–94.2 per cent). While 97 per cent of patients
underwent successful decannulation, and of the 197
patients where swallowing outcomes were reported,
194 achieved full oral intake.13 Supracricoid laryngect-
omy alone was assessed in a meta-analysis of 103
recurrent T1 and T2 glottic cancer14 and local control
could be achieved in 85 per cent. In the 15 per cent
who had further recurrence, two thirds could be
treated further with salvage laryngectomy.
Therefore, total laryngectomy is not the only option
for treatment of laryngeal recurrence, and transoral and
partial laryngectomy operations are feasible and highly
effective. It is recommended that the management of
patients with laryngeal recurrence includes input from
surgeons who have expertise in transoral and open
partial laryngectomy in the recurrence setting, and
that this expertise is limited to a small number of sur-
geons providing regional services.
Recommendations
• Management of patients with laryngeal
recurrence should include input from
surgeons with experience in transoral surgery
and partial laryngectomy for recurrence (G)
• Expertise in transoral surgery and partial
laryngectomy for recurrence should be
concentrated to a few surgeons within the
MDT (G)
• Transoral or open partial laryngectomy
should be offered as definitive treatment
modality for appropriate highly-selected
patients with recurrent laryngeal cancer (R)
Oropharynx. Recent data suggest that the outcomes of
treatment of oropharyngeal recurrence have steadily
and markedly improved over the last two decades. In
a meta-analysis of five-year outcomes, survival out-
comes are reported to have increased from 18 per
cent for patients treated before the year 2000 to 51
per cent for patients treated after the year 2000.2 It
would also appear that the reported complication
rates have also decreased considerably over that
period of time. This improvement in outcomes may
be due to a combination of several factors: better
intra- and post-operative care, better use of reconstruct-
ive techniques, better patient selection and also the pos-
sible role of HPV. Recent data suggest that patients
with HPV-positive recurrence of the oropharynx have
longer survival rates than patients with HPV-negative
recurrence.4 Importantly, those patients who are HPV
positive and who received surgical resection had sig-
nificantly better outcomes than the other groups. This
would suggest that there is a need for a change in the
traditional view that patients with oropharyngeal
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cancer have very poor outcomes, and therefore are
often offered palliative treatments instead of curative
resections. It should, however, also be noted that surgi-
cal treatment of recurrence carries significant complica-
tion rates as well as considerable functional deficits,
with reports on return to oral intake varying from 44
to 68 per cent.8 Successful resection of oropharyngeal
recurrence can be difficult due to the complex three-
dimensional anatomy and proximity and adherence to
the internal carotid artery. Access procedures through
mandibulotomy or lingual release are usually required.
Discussion with oncology colleagues regarding areas
of highest RT delivery can help plan the siting of the
mandibulotomy, as a median mandibulotomy may
avoid the areas of the mandible that received the
highest RT dose, and therefore avoid the areas at
highest risk of osteoradionecrosis. Lingual release is
also a good option, but provides limited access to the
superior aspects of lateral tonsillar extensions, and
may result in higher functional morbidity.
Recommendations
• Patients with oropharyngeal recurrence
should have p16 HPV status assessed (R)
• Patients with oropharyngeal recurrence
should be considered for salvage surgical
treatment by an experienced team, with
reconstructive expertise input (G)
• Transoral surgery appears to be an effective
alternative to open surgery for the
management of oropharyngeal recurrence in
carefully selected patients (R)
Recently the advent of transoral surgery, and especially
transoral robotic surgery (TORS), has facilitated better
transoral access to the oropharynx.15 This approach is
now being utilised for surgical resection of smaller
OPC recurrences with good outcomes. A recent multi-
centre case–control study showed that salvage patients
treated with transoral robotic surgery had significantly
lower incidence of tracheostomy, feeding tube use, and
shorter hospital stay, with significantly decreased inci-
dence of positive margins and significantly higher sur-
vival than matched patients treated with open surgery.
Nasopharynx. This is the one area traditionally where
re-irradiation has been employed for salvage treat-
ment, particularly where the recurrent disease is
limited to the confines of the nasopharynx without
extensive invasion of the bone of the skull base or
intracranial structures. In areas of the world where
major centres treat large numbers of these patients,
notably Southern China, Hong Kong and Singapore,
surgery for localised recurrent disease has been under-
taken by means of maxillary swing or other forms of
anterior mid-facial approaches. With varying degrees
of nasopharyngectomy, cure rates in selected patients
have been reported in the region of 40 per cent at
five years.
Sinus and nasal cavity. Despite the rarity of these
tumours and the diversity of pathology in these areas,
salvage treatment can achieve good long-term cure
rates in carefully selected patients. Endoscopic endona-
sal surgery is showing comparable outcomes and is the
treatment of choice in certain situations for both
primary and recurrent disease when compared with
conventional open approaches.
Many recurrent tumours such as adenoid cystic car-
cinoma, chondrosarcoma, intestinal type adenocarcin-
oma and olfactory neuroblastoma will need a
multimodality, multidisciplinary approach, which can
only be effectively provided in large centres that have
the expertise both in endonasal and in open anterior
and anterolateral craniofacial resection. The tumour
biology as well as its location determines the best
approach. Oncological goals do not change in the endo-
scopic endonasal route with the goal being negative
resection margins. En-bloc resection is often not pos-
sible. Despite this, outcomes in both overall survival
and disease-free survival are comparable with open
approaches and should be considered as a viable treat-
ment option for recurrences.
Neck and nodal disease. Neck dissection in the salvage
context may carry higher complication rates than in the
primary setting. The type of neck dissection also has a
bearing on complication rates, with modified radical
neck dissections or radical neck dissections carrying
higher major complication rates than selective neck
dissections in the salvage setting. Furthermore, neck
dissection was found to be a significant risk factor
for pharyngocutaneous fistula after laryngectomy in a
meta-analysis.16 Studies looking at avoiding neck dis-
section in patients with recurrence at the primary site
with no clinical evidence of nodal metastasis have
shown that whilst the neck dissection is associated
with higher complication rates, there was also a
lower regional failure rate. On the other hand, other
studies have found the pre-operative clinical staging
of nodal status in patients undergoing salvage laryn-
gectomy to be highly accurate.17 Therefore it would
appear that undertaking elective neck dissections in
patients with N0 necks following recurrence should
be considered, especially in patients with advanced
recurrences.
As for patients with proven nodal recurrent disease,
selective neck dissection is also as effective as modified
radical neck dissections, but potentially carries less
morbidity.18 The evidence would suggest that using
selective neck dissection reduces complication rates
and results in similar control rates to more radical
neck dissection in recurrence patients who have N0.
Indeed, some have suggested that superselective neck
dissection is also effective, although the evidence
level for this is weak.19
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Recommendations
• Consider elective selective neck dissections in
patients with recurrent primaries with N0
necks, especially in advanced cases (R)
• Selective neck dissection (with preservation of
nodal levels, especially level V, that are not
involved by disease) in patients with nodal
(N+) recurrence appears to be as effective as
modified or radical neck dissections (R)
Reducing complications in salvage surgery
There are interventions that are proven to reduce compli-
cations in salvage surgery. These include the following:
• Use of Montgomery salivary bypass tubes has been
shown to decrease fistula rates and has also been
shown to be cost-effective in laryngectomy20
• The use of flap closure for pharyngeal defects if
there is any tension on wound closure has been
shown to decrease fistula rates. A meta-analysis
showed that use of a vascularised flap to augment
the circumference or support the repair reduces
the risk of fistula formation by one-third.13 Flap
reconstruction also reduces stricture rates and tube
dependence compared with primary closure. The
use of a pectoralis major pedicled-flap or a free
flap is therefore recommended
• In patients where there is no tension at the anasto-
motic site, interposition flap reinforcement of the
suture line has been shown to decrease fistula
rates. This may be undertaken using a pectoralis
major myofascial pedicled flap or an interposition
free flap, both of which have been shown to reduce
fistula rates13
• Secondary puncture has also been shown to
reduce fistula rates in post-chemoradiotherapy
salvage laryngectomies. Although no literature
evidence exists, avoidance of three-point junc-
tions in skin incision through the use of horizon-
tal incisions (e.g. Attee or MacFee) may help
reduce wound breakdown.
Palliative chemotherapy
Patients receiving only palliative care have an average
overall survival of four months after diagnosis.
Outcomes from studies of palliative chemotherapy
generally show longer survival rates, depending on
the regimen. However, no large well-designed rando-
mised trial has been undertaken to definitively show
an overall survival benefit of palliative chemotherapy
over the best supportive care in these patients.
Several chemotherapy regimens, either single agent
or combination treatments have been tried in recurrent
head and neck squamous cell carcinoma patients with
different results. The active single agents in head and
neck squamous cell carcinoma patients with response
rates greater than 15 per cent include methotrexate,
bleomyin, cisplatin, carboplatin, paclitaxel, docetaxel,
cyclophosphamide, doxorubicin, hydroxyurea, vinblast-
ine and fluorouracil (5-FU). Various randomised trials
have been undertaken to compare different chemo-
therapy regimens in recurrence patients. Combination
treatment has shown higher response rates than the
single-agent therapy.
In comparison with PF (cisplatin 100 mg/m2 and
5-FU 750 mg/m2 days 1–5 every three weeks) in a ran-
domised controlled trial, TPF induction chemotherapy
(docetaxel 75 mg/m2, cisplatin 75 mg/m2 and 5-FU
750 mg/m2 days 1–5 every three weeks) was shown
to yield a higher objective response rate as well as
increased median progression-free and overall survi-
vals in unresectable head and neck cancer patients
without distant metastasis. However, this regimen is
mainly used as induction chemotherapy before radical
treatment for curative patients and it is not normally
used as first line treatment in recurrent or metastatic
head and neck squamous cell carcinoma patients with
unresectable disease due to significant toxicities asso-
ciated with this regimen.21 Some of the selected
chemotherapy regimens commonly used in palliative
head and neck squamous cell carcinoma patients are
listed in Table I.
Recommendations
• Use salivary bypass tubes following salvage
laryngectomy (R)
• Use interposition muscle-only pectoralis
major or free flap for suture line
reinforcement if performing primary closure
following salvage laryngectomy (R)
• Use inlaid pedicled or free flap to close wound
if there is tension at the anastomosis following
laryngectomy (R)
• Perform secondary puncture in post CRT
laryngectomy patients (R)
Since a majority of head and neck squamous cell carcin-
oma tumours express or overexpress epidermal growth
factor receptor, the epidermal growth factor receptor
inhibitors including cetuximab has been tried in these
patients. A phase III randomised trial of cisplatin plus
placebo compared with cisplatin plus cetuximab in meta-
static and/or recurrent head and neck cancer was done
and it was shown that addition of cetuximab to cisplatin
significantly improved response rate but did not signifi-
cantly improve progression-free and overall survival.22
The addition of cetuximab to platinum-based chemo-
therapy (either cisplatin 100 mg/m2 or carboplatin are
under the curve 5 with 5-FU 750 mg/m2 days 1–4
every three weeks) improved objective response rate,
median progression-free and overall survivals compared
to platinum-base chemotherapy alone (EXTREME
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trial).23 This regimen is recommended as the first-line
systemic treatment for recurrent and metastatic head
and neck squamous cell carcinoma patients with good
performance status in many centres. However, the
choice of EXTREME regimen as first-line treatment
will depend on individual patient circumstances and per-
formance status. In England, cetuximab in addition to 5-
FU and platinum chemotherapy could be prescribed in
the NHS through the cancer drug fund although this
fund is not available in other parts of the UK and may
only be available in the a short term. As the regimen is
associated with high frequencies of toxicities, not all
patients can tolerate or complete the treatment.
For patients who are deemed to be unfit to have
EXTREME regimen, a modified version of cetuximab
and a platin or reduced doses have been used for some
patients. In addition, if cetuximab is not used or not
available, many centres will use the combination plat-
inum-based regimens (without cetuximab) as first-line
treatment for these recurrent head and neck squamous
cell carcinoma patients, including those regimens
listed in Table I.
Once patients have progressed on platinum based
chemotherapy, the prognosis is extremely poor and
there is no standard second-line or third-line therapy
for these patients. In some cases, another platinum-
based combination chemotherapy can be given as
second line, e.g. carboplatin and paclitaxel. However,
some of these patients may have deteriorating or poor
performance status and further combination chemo-
therapy treatment may be poorly tolerated. In addition,
some patients may be platinum-resistant and are unlike-
ly to benefit from further platinum-based chemother-
apy. For second- or third-line chemotherapy, single
agent taxane (paclitaxel or docetaxel) or methotrexate
has also been used in patients who still have relatively
good performance status.
For patients who are unfit to have palliative chemo-
therapy, best supportive care may be the best option,
since palliative chemotherapy may worsen their
quality of life without a survival benefit. This decision
needs to be made by the doctors and patients together,
with the involvement of a palliative care physician,
focusing on the benefits of palliative chemotherapy
vs the risks of treatment toxicity.
Patients with non-resectable recurrences being con-
sidered for palliative treatment should be offered the
opportunity to participate in clinical trials of new thera-
peutic agents, including immunotherapy. If such trials
are not available locally, patients should be referred
to centres that offer these trials.
Recommendations
• Triple therapy with platinum, cetuximab and
5-fluorouracil appears to provide the best
outcomes for the management of patients with
recurrence who have a good performance
status and are fit to receive it. If not fit, then
combinations of platinum and cetuximab or
platinum and 5-FU may be considered (R)
• Patients with non-resectable recurrent disease
should be offered the opportunity to
participate in Phase I-III clinical trials of new
therapeutic agents (R)
Re-irradiation
Most patients with recurrence will have had previous
radical RT, which would have reached the maximal
TABLE I
SELECTED PALLIATIVE CHEMOTHERAPY REGIMENS COMMONLY USED IN RECURRENT OR METASTATIC HEAD AND
NECK SQUAMOUS CELL CARCINOMA PATIENTS (MODIFIED FROM REFERENCES 1–2)
Regimens Usual doses Response
rate (%)
Reference
Cetuximab/5-FU/cisplatin Cisplatin IV 100 mg/m2 q3w
5FU IV 1000 mg/m2 d1–4 q3w
cetuximab IV 400 mg/m2 loading dose
and 250 mg/m2 maintenance dose q1w
36 Gao et al.6
Cisplatin/5-FU Cisplatin IV 100 mg/m2 q3w
5FU IV 1000 mg/m2 d1–4 q3w
27–50 Jayaram et al.2, Zafereo et al.8,
Paleri and Kelly9
Cisplatin/paclitaxel Cisplatin IV 75 mg/m2 q3w
paclitaxel IV 175 mg/m2 q3w
26–41 Zafereo et al.8, Steiner et al.10
Cisplatin/docetaxel Cisplatin IV 75 mg/m2 q3w
docetaxel IV 75 mg/m2 q3w
53 Roedel et al.11, Ramakrishnan
et al.12
Carboplatin/paclitaxel Carboplatin IV AUC 6 q3w with
paclitaxel IV 200 mg/ m2 q3w or
carboplatin IV AUC 2 q1w with
paclitaxel 80 mg/m2 q1w
27
52
Paleri et al.13, Marioni et al.14
Docetaxel Docetaxel 75–100 mg/m2 q3w 21–42 White et al.15, Paydarfar et al.16
Paclitaxel Paclitaxel 80–100 mg/m2 q1w
paclitaxel 175 mg/m2 q3w
13–40 Pezier et al.17, van der Putten
et al.18
Methotrexate Methotrexate 40–60 mg/m2, q1w 10–77 Dunsky et al.7, Robbins et al.19,
Murray et al.20
IV= intravenous; q3w= every three weeks; q1w= every week; d1–4= days 1–4
Note: some of the trials used different doses and regimens than those listed as ‘usual’ doses.
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acceptable tolerance dose for critical organs such as
spinal cords and/or brainstem. Therefore, re-irradiation
of these patients carries significant potential risks and
complications.
Patient selection
Data on patient selection for chemo re-irradiation is
sparse, with comorbidity and pre-existing organ dys-
function being the most important prognostic factors
for patients undergoing re-irradiation. Other prognostic
factors include interval from previous radiation, recur-
rent tumour stage, tumour bulk at re-irradiation, and re-
irradiation dose.24
Re-irradiation using conventional and older RT
techniques for unresectable recurrent cancers
Some single centre and phase 2 studies have shown
very good control rates for re-irradiation of recurrent
tumours with prolonged survival rates. However, repli-
cation of these results in phase 3 studies has not mate-
rialised, probably reflecting in part the importance of
specialist expertise and careful patient selection. At
the Gustave-Roussy Institute, full-dose re-irradiation
was given to 169 patients with unresectable head and
neck cancer, in the form of either RT alone or with con-
current chemotherapy (5-FU and hydroxyurea or mito-
mycin, 5-FU and cisplatin). The overall survival (OS)
rate was 21 per cent at 2 years and 9 per cent at 5
years, with a median survival time of 10 months for
the whole population. In the RTOG 96–10 study, 86
patients received re-irradiation with 5-FU and hydro-
xyurea. The two- and five-year survival rates were
15.2 and 3.8 per cent respectively with overall grade
3–4 acute toxicities of 56 per cent, grade 3–4 late toxi-
cities of 22 per cent and deaths in 8 per cent of
patients.25 In the RTOG 99–11 study, recurrent head
and neck cancer patients received twice-daily radiation
(1.5 Gy per fraction bid 5 days every 2 weeks with low-
dose paclitaxel and cisplatin). The estimated one- and
two-year OS rates were 50.2 and 25.9 per cent, respect-
ively. The study also showed 28 per cent grade 4–5
acute toxicities and 11 per cent treatment-related
deaths.
A randomised phase III trial (Groupe d’Oncologie
Radiotherapie Tete Et Cou (GORTEC) 98–03) com-
pared re-irradiation with 5-FU and hydroxyurea
chemotherapy with palliative methotrexate monother-
apy in patients with recurrent or a second primary
head and neck squamous cell carcinoma.26 Despite
the promising phase II studies, this phase III study
showed that re-irradiation with concurrent chemother-
apy did not improve OS compared with methotrexate
alone (23 per cent vs 22 per cent at one year, NS).
There were however four complete responses in the
re-irradiation arm, and none in the chemotherapy
alone arm. Twenty-eight per cent had grade 3 late tox-
icity in the re-irradiation arm compared with 9 per
cent in the chemotherapy arm. The trial was closed
prematurely and thus no definite conclusion could
be drawn.
The Groupe d’Étude des Tumeurs de la Tête et du
Cou (GETTEC) and Groupe d’Oncologie Radiothera-
pie Tête Et Cou (GORTEC) undertook a randomised
study examining the efficacy of adjuvant chemo re-
irradiation after salvage surgery. The study included
patients who had salvage surgery with no gross residual
disease and a good performance status. Patients were
randomised to either observation or post-operative
chemo re-irradiation (FHX (5-fluoro-uracil, hydroxyurea
and radiation) regimen, daily radiation to 60 Gy).
Patients in the post-operative chemo re-irradiation arm
had significantly improved locoregional control (49
per cent vs 25 per cent) and disease-free survival.
However, there was no significant difference in overall
survival due to an increase in treatment-related deaths
and second primary tumours following chemo re-irradi-
ation, with 40 per cent of patients experiencing grade 3
or 4 late toxicity in the chemo re-irradiation arm, com-
pared to 10 per cent in the observation arm.
Re-irradiation with intensity-modulated radiotherapy
(IMRT)
Intensity-modulated radiotherapy (IMRT) can poten-
tially limit the dose to critical areas. At the same
time, however, it may increase the dose to surrounding
non-critical areas. Therefore, it is not yet completely
clear what the balance of benefit and harm will be.
In one study, 105 patients with recurrent head and
neck cancer underwent re-irradiation using IMRT
(75 of whom also received concurrent chemotherapy)
and the two-year locoregional progression-free sur-
vival and overall survival rates were 42 and 37 per
cent, respectively. The acute and late grade 3 toxicities
were reported in 23 and 15 per cent of patients respect-
ively. In another study, 84 patients underwent re-irradi-
ation using IMRT (20 per cent received concurrent
chemotherapy), five-year locoregional control and
overall survival were 40 and 20 per cent respectively,
with grade 3 acute and late toxicities of 31 and 13 per
cent. Although there was no grade 5 acute toxicity,
there were two fatal vascular ruptures during follow-up.
Re-irradiation with biological therapies
The combination of an epidermal growth factor recep-
tor inhibitor, cetuximab, with RT has been shown to
significantly improve overall survival at five years
compared with RT alone for locoregionally advanced
head and neck cancer. Therefore, there is also rationale
for combining cetuximab with re-irradiation in recur-
rent head and neck cancer patients. One recent study
showed a median overall survival of 10 months in
recurrent head and neck cancer patients retreated with
stereotactic body radiation therapy plus cetuximab.
Acute and late grade 3 toxicity was observed in 6 per
cent of patients, which seems to be much lower than
that of re-irradiation and chemotherapy.
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Toxicity of chemo re-irradiation
Chemo re-irradiation carries risk of very severe life-
threatening toxicity, which has to be weighed against
the relative survival benefit, and quality of life detri-
ment. The resultant acute major toxicities are similar
to those of primary chemoradiotherapy, including
mucositis, dermatitis and hematologic suppression.
These toxicities generally resolve after the completion
of therapy, and most patients recover with supportive
measures, although treatment interruptions may be
necessary. Compared with re-irradiation alone, the add-
ition of concurrent chemotherapy significantly
increases acute toxicities.
Late toxicities are generally less predictable and irre-
versible, and therefore carry a higher potential for pro-
blems. In RTOG 9610, the cumulative incidence of
grade 3+ late toxicity in patients surviving more than
1 year was 12.3 per cent. The most worrisome late com-
plications are neurological toxicities as well as carotid
rupture. Fortunately, these devastating complications
occur rarely, even in patients who receive large lifetime
radiation doses.
Recommendations
• Chemo re-irradiation appears to improve loco
regional control, and may have some benefit
for overall survival, at the risk of considerable
acute and late toxicity. Benefit must be
weighed carefully against risks, and patients
must be counselled appropriately (R)
• Target volumes should be kept tight and
elective nodal irradiation should be avoided
(R)
Treatment volume definition
In re-irradiation, the potential benefit and toxicity of
elective nodal irradiation need to be carefully consid-
ered, since the risk of toxicity is generally related to
the volume of tissue irradiated. The literature suggests
that the major risk of recurrence is within the region of
gross recurrent disease. The probability of isolated
failure in the electively treated areas is low. Treatment
volume of the gross tumour should be expanded by a
safety margin of 1–1.5 cm. Prophylactic treatment of
draining lymphatic regions is generally avoided. In
areas closely abutting critical structures, the margin
may be smaller to reduce the risk of complications.
After surgical resection, only the tumour bed of the
high-risk areas (e.g. positive margin and extracapsular
extension) is usually targeted.
Best supportive care
Palliative and best supportive care should be offered
routinely as part of the management package of all
recurrence patients, even in the case of those who are
being treated curatively. The early involvement of the
palliative care physician can help control symptoms
in the lead up to curative or palliative treatment.
Furthermore, it provides a more seamless transition
into palliative care if required. Involvement of a pallia-
tive care physician gives the patients confidence that
their symptoms will be managed regardless of the out-
comes of the treatment, and also can speed up the pro-
vision of support for patient and family at home.
Key points
• Recent evidence suggests that outcomes of the
management of recurrence are not as dire as is
widely considered
• Evaluation and careful selection of patients with
recurrence is the crux of successful management
• PET CT scanning is the most effective imaging
method for the evaluation of recurrence
• Surgery appears to give the best outcomes for the
management of recurrence, especially if HPV
positive, but also has a high complication rate
• Patients who have the best outcomes from treat-
ment are those with small recurrences and
second primaries who do not smoke or who
have stopped smoking, and have good perform-
ance status, and in whom the tumour can be com-
pletely removed with no involved margins,
especially if chemoradiotherapy can be given
afterwards if indicated
• The standard regimen for first-line palliative chemo-
therapy is cisplatin, 5-FU and cetuximab. However
some patients may not be able to tolerate it
• Re-irradiation using tight target volumes may
improve locoregional control, but does carry sig-
nificant risk of toxicity
• Patients with recurrence often have significant
symptoms, and should be offered best supportive
care interventions regardless of the intent of
therapy, as they can benefit from assessment and
management by pain control teams and other
clinicians.
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